Social Media Toolkit

Association for Accessible Medicines

2026 U.S. Generic & Biosimilar Medicines Savings Report

FORWARD FOR AMERICA

Generic and biosimilar medicines saved America's patients and the U.S. healthcare system $496B in 2025. This is solid proof: generic and biosimilar medicines provide immense value to the U.S. healthcare ecosystem. But the generic and biosimilar medicines industry is more than the backbone of affordable healthcare in America, it is a driving force of strength, stability, and security in the U.S.

Responsible for 89% of all prescriptions filled by Americans, generics and biosimilars have ***extreme potential*** to be a catalyst for domestic job creation, foster national security and bolster healthcare and economic resilience. **WE CANNOT LET THIS POTENTIAL SLIP AWAY.** With enormous saving at risk and value compression in the U.S. market, now is the time for the Administration, policymakers, regulators, and industry advocates to take actions that move generic and biosimilar medicines forward, by removing structural obstacles that prevent healthy competition from functioning the way it was designed to function, in America.

Please utilize this social media toolkit across your digital channels. Copy, paste and post—and tag **@accessiblemeds** and **@biosimilarscouncil**. Doing so will help urge policymakers to ensure patients are never forced to choose between their medicines and their livelihoods.

Thank you for your help spreading the word! Your efforts amplifying the social content below will ***help move generic and biosimilar medicines forward for America***, ensuring patients across the U.S. can always have access to the medicines they need to thrive!

#GRxBiosimsSavingsReport

The 2026 Savings Report

- AAM Website: accessiblemeds.org
- AAM Report Page: https://accessiblemeds.org/resources/blog/2026-savings-report
- Biosimilars Council Website: biosimilarscouncil.org
- Biosimilars Council Report Page: https://biosimilarscouncil.org/resource/2026-savings-report

Follow AAM

/accessiblemeds

Follow Biosimilars Council

/biosimscouncil

Help Spread the Word

We encourage you to utilize the info in this toolkit to help raise awareness around the benefit of generic and biosimilar medicines—as well as the impact policy and regulatory decisions can have on the sustainability of this essential industry. Please post on any or all of your favorite social media channels and please include the hashtag #GRxBiosimsSavingsReport. Please also consider tagging @accessiblemeds and @biosimscouncil – so we can share your message on our channels, too!

Social-Ready Graphics

Download all images here

Hashtags

Questions? Please email the AAM Communications Department at: media@accessiblemeds.org

#GRxBiosimsSavingsReport #Generics #GenericMedicines #Biosimilars



Short: JUST RELEASED! The 2026 U.S. Generic & Biosimilar Medicines Savings Report shows $3.6 TRILLION of savings in the last decade, positioning these lower-cost treatment options as a force of strength and security in the U.S. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: JUST RELEASED! The 2026 U.S. Generic & Biosimilar Medicines Savings Report shows $3.6 TRILLION of savings in the last decade, positioning these lower-cost treatment options as a force of strength and security for both the U.S. healthcare ecosystem and the economy. Access the full report to learn how Generic & Biosimilar Medicines are Driving America FORWARD! https://accessiblemeds.org/resources/reports/2026-savings-report/

Short: Generic and biosimilar medicines are indispensable—$496B in savings in 2025 alone underscores this point. But the market that sustains the only industry bringing lower, year-over-year costs to American patients is at risk. A generics and biosimilars first policy framework is imperative to keep the savings moving forward. Learn More: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: Generics Forward for America's Patients! Generic and biosimilar medicines are indispensable—$496B in savings in 2025 alone underscores this point. But the market that sustains this industry is at risk. Policymakers must streamline FDA processes, curb patent abuse, stop pharmacy benefit managers (PBMs) and Medicare policies from favoring higher priced brands, and roll back harmful federal policies like Inflation Reduction Act (IRA) price controls that suppress investments in new generics and biosimilars. With the removal of these obstacles, we can move generic and biosimilar medicines forward and bring more affordable prescription options to the millions of patients who rely on them to feel well and thrive. https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: Generic and biosimilar medicines are indispensable—$496B in savings in 2025 alone underscores this point. But the market that sustains the only industry bringing lower, year-over-year costs to American patients is at risk. A generics and biosimilars first policy framework is imperative to keep the savings moving forward. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: Generics Forward for America's Patients! Generic and biosimilar medicines are indispensable—$496B in savings in 2025 alone underscores this point. But the market that sustains this industry is at risk. Policymakers must streamline FDA processes, curb patent abuse, stop pharmacy benefit managers (PBMs) and Medicare policies from favoring higher priced brands, and roll back harmful federal policies like Inflation Reduction Act (IRA) price controls that suppress investments in new generics and biosimilars. With the removal of these obstacles, we can move generic and biosimilar medicines forward and bring more affordable prescription options to the millions of patients who rely on them to feel well and thrive. https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: Annual savings from generic & biosimilar medicines totaled $496B in 2025, more than $25B of that came from biosimilars medicines. Yearly savings from both generic & biosimilar medicines increaed by nearly $30B compared to 2024. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: 2026 Savings Report data is in, and savings from generic & biosimilars totaled $496B in 2025—an increased of ~$30B from previous year! Even better news: Patient sentiment aligns. A 2025 survey showed 90% of patients noting that they would be happy if their doctor switched them to a less expensive medication, and 85.5% preferred if prescribers defaulted to the lowest-cost option, whenever clinically appropriate. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: The biosimilars market is rapidly growing! After 10 full years in the U.S. market, we know that biosimilar medicines have been used in over 3.8 billion days of patient therapy, with no clinically meaningful differences in safety or efficacy! Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: The biosimilars market is rapidly growing! After 10 full years in the U.S. market, we know that biosimilar medicines have been used in over 3.8 billion days of patient therapy, with no clinically meaningful differences in safety or efficacy! But biosimilar adoption has been slower than anticipated. 90% of brand biologics losing exclusivity between 2025 & 2034 do not currently have a biosimilar in development. This biosimilar void is dangerous for U.S. healthcare resilience and will create access issues to lower-cost treatment options for America's patients. Policymakers must take action now and ensure policy and regulatory conditions are in place for quicker adoption. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: 2026 Savings Report data reveals generic medicines as the backbone of U.S. healthcare, accounting for 89% of all prescriptions filled, but only 11.6% of total drug spending. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: 2026 Savings Report data reveals generic medicines as the backbone of U.S. healthcare, accounting for 89% of all prescriptions filled, but only 11.6% of total drug spending. Generic and biosimilar medicines are the only segment of healthcare that consistently delivers lower costs. Generic medicines save patients money. In 2025, the average out-of-pocket cost for a generic was $6.67; while the average out-of-pocket cost for a brand drug was nearly five times higher at $33.58. But here's the problem: generic prices continue to experience severe deflation; the overall value of all generic sales in the U.S. has declined by $6.4 billion since 2019, despite increased volume and new generic launches. This price deflation is a unique characteristic of the generic market—and without purposeful action from policymakers and regulators, these conditions could put the market, and American patients, in peril. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: In 2025, generic & biosimilar medicines accounted for scarcely more than 1% of total spending on healthcare. At the same time, these lower-cost prescription options accounted for 89% of ALL prescriptions filled in the United States. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: In 2025, generic & biosimilar medicines accounted for scarcely more than 1% of total spending on healthcare. At the same time, these lower-cost prescription options accounted for 89% of ALL prescriptions filled in the United States. All in, in the last 10 years, the U.S. healthcare system has saved $3.6 trillion due to the availability of affordable generic and biosimilar medicines. And in 2025 alone, competition from generics and biosimilars resulted in more than $496 billion in savings to the healthcare system. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: In the U.S., what makes generics structurally different from brand medicines is not chemistry. It's economics. Because of this, prioritizing generic and biosimilar medicines, as a unique market is essential for sustainable patient access. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: In the U.S., what makes generic medicines structurally different from brand drugs is not chemistry. It's economics. Generics and biosimilars operate in distinct markets from their brand counterparts. Here's an example that shows the uniqueness of the generic medicines market, compared to brand drugs: In 2025, for 1,106 molecules, the entire generic market cultivated $57B in sales. At the same time, only two brand drug products – Mounjaro and Ozempic – captured $76.4 billion in sales. That's nearly 50% more in sales from those two products alone, than all 1,106 generic molecules combined. If not prioritized through policy and regulatory actions, lower-cost generic and biosimilar medicines could be forced out of the U.S. market, entirely. This can yield supply chain disruptions and drug shortages, and negatively impacts our resilience as a nation with the potential for economic uncertainties and national security threats. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: The economics of the generics market have deteriorated to the point where sustainability of the industry is in peril. This is alarming and must be a cause of great concern for policymakers, in terms of healthcare and economic resilience and national security. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: Unsustainable deflation has put savings from generic and biosimilar medicines in jeopardy! The economics of the generics market have deteriorated to the point where sustainability of the industry is in peril—igniting the potential for drug shortages, supply chain disruptions and general healthcare and economic resilience concerns. This is alarming and must be a cause of great concern for policymakers. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: A recent IQVIA analysis shows substantially more generics filled at substantially lower costs in America, compared to other regions. https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: A recent IQVIA analysis shows substantially more generics filled at substantially lower costs in America, compared to other regions. Across the globe, the overall share of the prescription drug market has increased for generics and biosimilars. Unfortunately, while the overall share of the market has increased, the amount of spending on those same products within certain regions has tended to decrease. Other areas of the world did not show such dramatic price deflation. Learn More: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: 2026 data from AAM shows a complex system where the number of patents asserted in the U.S. can be more than 10 times that of other countries. The result? Delayed patient access to lower cost medications and delayed patient savings. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: The AAM 2026 U.S. generic & biosimilar medicines industry savings report shows patent litigation as more complex in the U.S., which negatively impacts patient access. The bottom line: Patent abuse in the U.S. must be stopped! Patent litigation in the U.S. is far different—and more complex—than other countries. A critical difference between the U.S. versus Canada and the U.K. is the sheer number of patents asserted. As indicated in the chart above, the number of patents asserted in the U.S. can be more than 10 times that of other countries. This complex litigation delays patient access to lower-cost products. As a result, patients and taxpayers pay more—for a longer duration of time. Policymakers must work to limit the number of patents brand-drug manufacturers can assert and prevent anticompetitive practices that delay patient access to biosimilars. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: A stable U.S. generics market leads to healthcare and economic resilience and sustained patient care. But an instable generics market can lead to drug shortages, which negatively impacts patient care. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: A stable U.S. generics market leads to healthcare and economic resilience and sustained patient care. But an instable generics market can lead to drug shortages, which negatively impacts patient care. According to the latest data, the U.S. faces continued drug shortages, especially among lower-cost generics. The shortage problem in America stems from consolidated purchasing power and lower reimbursement for generic drugs compared to other countries—which results in differences in profit margins between various generic markets. To address these issues, policymakers must provide a sustainable reimbursement plan, which does not focus solely on cost; and they must also address misaligned incentives. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

The Top 10 Products by Volume Represent 17% of the Overall Savings in the Past 10 Years

Top 10 Products by Volume in Past 10 Years						
Product	Generic Entry Year	Brand Pre-expiry Price (Per Unit)	Price Of Generic Equivalent 2024 (Per Unit)	10-year Savings ($B)	Percent Savings	10-year Volume Units Dispensed (B)
Glucophage	2001	0.66	0.03	49	88%	84.4
Neurontin	2003	1.02	0.05	72.1	94%	75.6
Lipitor	2010	3.29	0.06	202.2	98%	63.1
Toprol Xl	1993	0.41	0.05	19.1	82%	57.1
Norvasc	2006	1.54	0.02	73.3	99%	48.2
Zestril	1998	0.67	0.03	30.5	96%	47.6
Vicodin	1993	0.27	0.13	5.9	58%	38.2
Prilosec	2001	3.31	0.06	117.7	98%	36.3
Cozaar	2009	1.51	0.05	51.1	96%	35.3
Diprivan	1998	0.52	0.08	4.1	78%	28.8

Source: IQVIA National Prescription Audit, December 2025; IQVIA Institute, June 2026.

Short: Generic competition continues to generate billions of dollars in savings each year. It's important to remember this industry is built upon a high-volume model, enabling these lower-cost medicines to serve as a driving force of healthcare resilience and economic stability in the U.S. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: By volume, as indicated in the chart, the top 10 generics have saved $625B in the last decade, with discounts off the brand-drug price between 58% and 99%. Generic competition continues to generate billions of dollars in savings each year. It's important to remember this industry is built upon a high-volume model, enabling these lower-cost medicines to serve as a driving force of healthcare resilience and economic stability in the U.S. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: About 9 of 10 prescriptions filled the U.S. are generics and biosimilars, though the volume share of prescriptions dispensed of these lower-cost medicines varies significantly across therapy areas. Yet even when generic drugs are widely used, brand-name drugs may still account for the majority of spending. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: While approximately 9 out of every 10 prescriptions filled the U.S. are generics and biosimilars, the volume share of prescriptions dispensed of these lower-cost medicines varies significantly across therapy areas. For instance, generics account for 97% or more of the prescriptions for hypertension and mental health. However, for other therapy areas, it is much lower. Yet even when generic drugs are widely used, brand-name drugs may still account for the majority of spending. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: Savings from generic and biosimilar medicines brings patients relief from prescription costs and adds value, state by state! Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: Savings from generic and biosimilar medicines brings patients relief from prescription costs and adds value, state by state! On average, the use of generics and biosimilars saved more than $9.3 billion per state in 2025, with savings ranging from $651M in Alaska to $41.8B in California. Prioritizing the utilization of lower-cost generic and biosimilar medicines is a way for employers and state payers to ensure access and manage spending. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: As noted in the chart, examining the decreased costs and increased patient uptake after generic competition for Entresto makes it clear competition beats price controls. The bottom line: Healthy competition is the most proven approach to lowering drug costs. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: As noted in the chart, examining the decreased costs and increased patient uptake after generic competition for Entresto makes it clear that competition beats price controls. Entresto's MFP was set at $295 starting in calendar year 2026 for all Medicare beneficiaries. According to an AAM analysis of IQVIA data, the average cost of a patient prescription for all U.S. sales was a little over $1,000 in Q2 of 2025. When more than a dozen generic companies began marketing the product in Q3 of 2025, over time, the number of Americans being able to afford the drug increased, while the overall price of both the reference product and the generic competition decreased. The bottom line: Healthy competition is the most proven approach to lowering drug costs. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: Unfortunately, biosimilar adoption continues to trail expectations because of poor reimbursement and misaligned incentives. Still, biosimilar medicines have generated $81.6B in savings in the past decade—a reflection of provider confidence and healthy competition. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: Biosimilars are healthcare heroes—they promise additional savings for complex conditions, such as cancer and autoimmune diseases. Just as generics offer savings over brand drugs, biosimilars (the safe, effective alternative versions of biologic medicines) also promise to improve the quality of life for America's patients. All while, saving patients and the healthcare ecosystem billions of dollars. Unfortunately, biosimilar adoption continues to trail expectations because of poor reimbursement and misaligned incentives. Still, biosimilar medicines have generated $81.6B in savings in the past decade—a reflection of provider confidence and healthy competition. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: The Biosimilar Void continues—closing the gap in development pipelines could mean an Additional $189B in savings for U.S. patients and the healthcare ecosystem. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: In examining all biological products that face patent expiration between 2025 and 2034, only 10% are currently staged to face biosimilar competition. The remaining products are, unfortunately, stuck in the Biosimilar Void. If regulatory and policy conditions become more conducive to new biosimilar development though, closing the current gap in development pipelines could mean an additional $189B in savings for U.S. patients and the healthcare ecosystem. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/



Short: Streamlining biosimilar development reduces costs and timelines to bring lower-cost treatment options to the U.S. market. And America's patients will benefit from more lower-cost treatment options. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Long: Streamlining reduces the investment burden for new biosimilars and expands options for patient care. Evolutions in biosimilar streamlining, taken together, could reduce the investment burden of development by approximately 50%, freeing up manufacturer resources, expanding pipelines, and bringing more of these important products to market, more efficiently, without compromising the evidentiary gold standard. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

aam
Association for Accessible Medicines

accessiblemeds.org

BIOSIMILARS COUNCIL™
A DIVISION OF AAM

biosimilarscouncil.org